Rein Therapeutics closes $57.5 million follow-on common stock offering

• Rein Therapeutics closed an underwritten public offering of 57,500,000 common shares at USD 1 per share, raising USD 57.5 million in gross proceeds.
• Deal size increased through the full exercise of the underwriters’ over-allotment option for an additional 7,500,000 shares.
• No warrants or other derivative securities were issued in the offering.
• Proceeds earmarked to fund the Phase 2 trial of LTI-03 in idiopathic pulmonary fibrosis through completion, support broader development work, working capital.
• Cash runway expected to extend into the first quarter of 2028 under the current operating plan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief on May 18, 2026, and is solely responsible for the information contained therein.